Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price & Analysis
Crinetics Pharmaceuticals, Inc. (CRNX) rose 0.10% to USD 83.73 as of July 25, 2026 at 03:10 UTC, according to Nexqual real-time market data.
CRNX last closed at USD 83.65; the session ranged USD 83.68–83.8 on volume of 2,324,191 shares. Market capitalization is $8.86B, with a 52-week range of USD 25.83–84 (NMS). Source: Nexqual, July 25, 2026 at 03:10 UTC.
Key Statistics (as of July 25, 2026 at 03:10 UTC)
| Price | USD 83.73 |
|---|---|
| Change | ▲ 0.10% (up) |
| Previous Close | USD 83.65 |
| Open | USD 83.75 |
| Day Range | USD 83.68 – 83.8 |
| 52-Week Range | USD 25.83 – 84 |
| Volume | 2,324,191 shares |
| Market Cap | $8.86B |
| Exchange | NMS |
Technical Analysis (CRNX)
Nexqual's technical model rates CRNX "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:10 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 94.46 (overbought) |
| vs SMA50 | Above (USD 49.33) |
| MACD | 11.54 (positive) |
Analyst Ratings (CRNX)
Wall Street analysts rate CRNX "Hold" based on 10 analysts, with a mean price target of USD 82.5 (range USD 55–90), per Nexqual as of July 25, 2026 at 03:10 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 82.5 |
| High Target | USD 90 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 2 / 12 / 0 |
Earnings (CRNX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1.18 |
| Revenue Estimate | $14.87M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.23 vs est -1.2 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -1.37 ▲ beat |
| 2025-09-30 | USD -1.38 vs est -1.25 ▼ miss |
| 2025-06-30 | USD -1.23 vs est -1.1 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:10 UTC.
Financials & Fundamentals (CRNX)
| Total Revenue | $18.07M |
|---|---|
| Revenue Growth (YoY) | +2873.40% |
| Gross Margin | +0.00% |
| Operating Margin | -1307.79% |
| Profit Margin | +0.00% |
| ROE | -39.17% |
| Debt / Equity | 3.74 |
| Current Ratio | 18.6 |
| Total Cash | $1.29B |
| Total Debt | $47.85M |
| Free Cash Flow | $-242.14M |
Source: Nexqual, July 25, 2026 at 03:10 UTC.
Financial Health Score (CRNX)
Nexqual rates Crinetics Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:10 UTC.
| Growth | Strong — Revenue +641% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.29B cash vs $48M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$242M, burning cash |
| Efficiency | Critical — ROE -39%, ROA -24.7% |
Ownership (CRNX)
| Insider Ownership | +1.59% |
|---|---|
| Institutional Ownership | +121.70% |
| Shares Outstanding | 105.84M |
| Float | 95.55M |
| Short % of Float | +15.38% |
Source: Nexqual, July 25, 2026 at 03:10 UTC.
Leadership (CRNX)
Crinetics Pharmaceuticals, Inc. is led by R. Scott Struthers (age 63), Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:10 UTC.
| Founder, President, CEO & Director | R. Scott Struthers (age 63) |
|---|---|
| Co-Founder & Chief Scientific Officer | Stephen F. Betz (age 59) |
| Chief Financial Officer | Tobin C. Schilke (age 50) |
Major Backers & Investors (CRNX)
Notable institutional backers of Crinetics Pharmaceuticals, Inc. include FMR, LLC, Farallon Capital Management LLC, Wellington Management, according to Nexqual as of July 25, 2026 at 03:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.95% |
| Farallon Capital Management LLC | 7.91% |
| Wellington Management | 7.74% |
| Driehaus Capital Management, LLC | 6.07% |
| Price (T.Rowe) Associates Inc | 5.08% |
| Janus Henderson Group PLC | 4.29% |
| Fidelity | 4.24% |
| EcoR1 Capital, LLC | 4.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.03% |
| BlackRock | 10.25% |
Source: Nexqual, July 25, 2026 at 03:10 UTC.
From Crinetics Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our discovery team has significant expertise in understanding and creating product candidates to influence the dynamic behavior of GPCRs and has developed a number of proprietary methods, techniques and tools that we 5 Table of Contents believe will enable us to efficiently and reliably evaluate newly synthesized molecules.
- We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology, which strengthen and maintain our proprietary position in the field of endocrinology.
- We believe our approach to developing novel small molecule product candidates that uniquely engage peptide hormone GPCRs will enable us to generate orally bioavailable, and potentially more selective, effective and better tolerated therapeutics for patients.
- CRN09682 (non-peptide drug conjugate for SST2 positive solid tumors) We have developed a first-in-class, non-peptide, non-radioactive NDC linking an SST2 agonist with the cytotoxic drug MMAE, via a spacer and a cleavable linker for the treatment of NETs and potentially for use in other solid tumors that express SST2, or SST2+ tumors.
Partnerships
- Paltusotine is also in development for acromegaly in Japan through our licensing agreement with SKK.
- This single-center, in-patient study is in collaboration with the NIDDK of the NIH.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | USD 35.4 | ▲ 1.14% |
| SRRK | Scholar Rock Holding Corporatio | USD 47.67 | ▼ 1.3% |
| REPL | Replimune Group, Inc. | USD 9.7 | ▼ 9.77% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.81 | ▼ 5.62% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.1 | ▼ 1.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:10 UTC. This page is informational and not investment advice.